AONN+ Joins Pfizer’s 7th Annual Advocacy Luncheon at ASCO 2026

News & Updates published on June 23, 2026 in News & Updates

Pfizer luncheon as ASCO 2026Candice Roth, MSN, RN, CENP, AONN+ Executive Director, joined advocacy leaders and patient focused organizations at Pfizer’s 7th Annual Advocacy Luncheon during ASCO 2026, where attendees heard directly from Pfizer leadership about the science and breakthrough medicines in development for cancer patients.

Speakers and panelists shared forward looking insights, and participants engaged in a meaningful dialogue around the role of artificial intelligence in advancing patient centered care and how advocacy voices can help shape the future of oncology innovation.

Pfizer also introduced the soft launch of Patient Advocacy360, a new framework unifying its patient centric partnerships. The luncheon concluded with an Amplify Humanity Quilt video, honoring the patients, caregivers, and advocates whose stories inspire our work.

Related Items
Colorectal Cancer Screening Update: with Andi Dwyer, MPH
News & Updates published on June 23, 2026 in News & Updates
In this interview, AONN+ Board of Trustees member Andi Dwyer discusses the American Cancer Society’s updated colorectal cancer screening guidelines, including new stool-based tests and the first-ever recommendation of an FDA-approved blood-based screening test, while emphasizing that colonoscopy and stool tests remain the most effective tools for early detection and prevention.
AONN+ Takes Part in CAR T Vision Coalition Event
News & Updates published on June 23, 2026 in News & Updates
Candice Roth, MSN, RN, CENP, and Monica Dean represented AONN+ at the launch of the first U.S. CAR T Vision to Action Blueprint, a stakeholder-driven initiative that provides practical strategies and tools to address access barriers and expand the use of CAR T-cell therapy for eligible patients nationwide by 2030.
AONN+ Member Announces Expansion of Reimbursement Codes
News & Updates published on June 2, 2026 in News & Updates
AONN+ Board Member Andrea (Andi) Dwyer helped lead a three-year collaboration with the CDC and policymakers that resulted in new ICD-10 codes for Lynch Syndrome, BRCA1, BRCA2, and Li-Fraumeni Syndrome, improving coverage and access to genetic testing and diagnostic services for patients.